Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-FU and LMWH for PVR prevention in pediatric RRD
NCT06166914Completed
- Sponsor
- Alexandria University
- Start
- Oct 2021
- Primary completion
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Randomised trial of fluorouracil and low molecular weight heparin calcium in Proliferative Vitreoretinopathy (PVR), sponsored by Alexandria University. Primary endpoint: Recurrent Retinal Detachment due to Proliferative Vitreoretinopathy at 12 weeks. Started Oct 2021; status: completed.
02
Drugs
fluorouracillow molecular weight heparin calcium
03
Conditions
Proliferative Vitreoretinopathy (PVR)
Beyond the preview
Go deeper on NCT06166914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06166914.